DOCSLIB.ORG

A Proposed Mechanism for the Thermotropic Effects of Pipradrol in the Rabbit

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Proposed Mechanism for the Thermotropic Effects of Pipradrol in the Rabbit University of the Pacific Scholarly Commons University of the Pacific Theses and Dissertations Graduate School 1983 A proposed mechanism for the thermotropic effects of pipradrol in the rabbit Stephen Franklyn Small University of the Pacific Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds Part of the Medicine and Health Sciences Commons Recommended Citation Small, Stephen Franklyn. (1983). A proposed mechanism for the thermotropic effects of pipradrol in the rabbit. University of the Pacific, Thesis. https://scholarlycommons.pacific.edu/uop_etds/2089 This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of Scholarly Commons. For more information, please contact [email protected]. - A PROPOSED MECHANISM FOR THE THERMOTROPIC EFFECTS OF PIPRADROL IN THE RABBIT A Thesis Presented to the Faculty of the Graduate School University of the Pacific In Partial Fulfillment of the Requirements of the Degree Master of Science - by Stephen Franklyn Small April 1983 ~ LIBRARY ~ ~ ' I ' ~, · SEP 2 31983 i' ~ ' ~ UNIVERS ITY OF THE PACIF.IO i ''''''''''''''' ''~'~'- 409919 ~ This thesis, written and submitted by - Stephen Franklyn Small is approved for r ecommendation to the Graduate Council, University of the Pacific. Department Chairman or Dean: - - :_-- Thesis Com/Ee: .!Uit'!::!J. Co-Chai rman 1J_durch . Co-Chairman - - ~'lvt /f - - -- Dated: I I - ACKNOWLEDGMENTS The author wishes to express his sincere appreciation - - to : -~- Dr. Marvin H. Malone, whose patience, sense of humor and generous gift of time and knowledge has made the com- pletion of this thesis possible. Dr. Raymond M. Quock for his inspiration and guida nce in initiating this study. Dr. Katherine Knapp, Dr. James Blankenship and Dr. David Fries for their interest in this study. -· The School of Pharmacy for the privilege of using their facilities. Fellow graduate students Mike Namba and John Byrne for their encouragement, assistance and friendship. Charles Green and the staff at Green Brothers Pharmacy for their support in the final phase of this study. Sandy Turner for her technical assistance and the - Turner family for their friendship and support. -~= My wife Sandi, and children, Genoa and Lisa, and my parents for their continuous support, love and encourage- ment throughout the course of this study. ii TABLE OF CONTENTS Page LIST OF TABLES . v LIST OF FIGURES vi INTRODUCTION. 1 Clinical Considerations. 4 Temperature Regulation . 6 Statement of the Problem 9 MATERIALS AND METHODS 13 RESULTS . 17 Effects of Pipradrol in Rabbits Pretreated with Dopamine Receptor Blockers . 18 Effects of Pipradrol in Rabbits Pretreated with Alpha-Adrenergic Receptor Blockers . 18 Effects of Pipradrol in Rabbits Pretreated with Serotonin Receptor Blockers ...... 20 Effects of Pipradrol in Rabbits Pretreated with Histamine Receptor of Blockers . 20 Effects of Pipradrol in Rabbits Pretreated with Cholinergic Receptor Blockers. 21 Effects of Pipradrol in Rabbits Pretreated with a Beta-Adrenergic Receptor Blocker . 21 Effects of Pipradrol in Rabbits Pretreated with a Central Nervous System Depressant. 21 Effects of Clonidine in Rabbits Pretr eated with HEAT . 22 Effects of Apomorphine in Rabbits Pretreated with Pimozide . 22 Effects of Successive Treatments of Pipradrol. 22 iii - TABLE OF CONTENTS - (continued) Page DISCUSSION. 65 CONCLUSIONS 76 REFERENCES. 78 APPENDIX A: CALCULATION OF AREA UNDER THE CURVE 84 APPENDIX B: PROGRAM AND ILLUSTRATIVE CALCULA- TIONS. 85 '- ! - iv - --- LIST OF TABLES Table Page I . Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with Various Known Receptor Blockers .. 23 II. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated by Intracelebro­ ventricular Administration of HEAT 27 I I I. Effects of Various Drugs and Pretreatments on the Colonic Body Temperature of Rabbits 29 IV. Evaluation of the Area-Under-the-Curve Data for the Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with Various Known Receptor Blockers. 31 ·- v. Evaluation of the Area-Under-the-Curve Data for the Colonic Temperature Effects of Pipradrol in Rabbits Pretreated by the Intracerebroventricular Administration of HEAT . 33 VI. Evaluation of the Area-Under-the-Curve Data for the Effects of Various Drugs and Pretreatments on the Colonic Body Tempera- ture of Rabbits. 34 v LIST OF FIGURES Figure Page 1. The Dose Res ponse of the Colonic Bo d y Temperature in Rabbits Given Pipradrol. 35 2. Colonic Temperature Effects of Pipradrol in Rabbits Pretreated with Chlo rpromazine 3 7 -- (-30 minutes). 3. Colonic Te mp e rature Effects of P i pradro l in Rabbits Pre treat e d with Haloperidol - - (-30 minutes) . 39 4. The Colonic Te mp e rature Effects of Pipradol and Apomorpine in Rabbits Pre treat e d with Pimozide (-60 minutes) . 41 5. Colonic Te mp e r ature Effects of P ipradrol in Ra bbits Pre treated with Phenoxyben zamine (-60 minutes). 43 6. Colonic Temperature Effects of P ipradrol i n Rabbits Pretreated with HEAT (-30 minutes) 45 7 . Colonic Te mp e r ature Effects of Pipradro l in Ra bbits Pretreated with HEAT (-15 minutes) 47 8 . Colonic Te mpera ture Effects of Pipradrol in Rabbits Pretr eated with Cinanserin (-60 minutes). 49 9 . Colonic Te mp e rature Effects of Pipradrol in Rabbits Pretr eat ed with Cyproheptadine ( - 30 minutes). 51 10. Colonic Temper ature Effect s of Pipradrol in Rabbits Pretreated with Diphenhydramine (-30 minutes). 53 11. Colonic Te mp e rature Effects of Pipradrol in Rabbits Pretreated with Atropine ( - 30 minutes). 55 vi LIST OF FIGURES (continued) Figure Page 12. Colonic Temperature Effects of Pipradrol in Rabbits Pr-treated with Propranolol (-30 minutes). 57 13. Colonic Temperature Effects in Pipradrol in Rabbits Pretreated with Pentobarbital (-30 minutes). 59 14. Colonic Temperature Effects of Clonidine in Rabbits Pretreated with HEAT (-30 minutes). 61 15. The Effect of Successive Treatments of Pipradrol on the Colonic Body Tempera­ ture of Rabbits. 63 16. Comparative Evaluation of Area-Under-The­ Curve Data for the Colonic Body Tempera­ ture Effect of Intravenous Pipradrol in Rabbits Pretreated with Various Known Re­ ceptor Blockers. 67 17. A Proposed Model for Thermoregulation Involving NE (Norepinephrine), Alpha­ Adrenergic Receptors, Nicotinic Acetyl­ choline Receptors and Muscarinic Acetyl­ choline Receptors. 70 vii INTRODUCTION Pipradrol HCl was developed in the early 1950s by the Wm. S. Merre ll Co., Cincinnati, Ohio, as a n ew chemical­ type s timula nt. Designate d by the company as MDR-108, it was shown to induce c h anges in the activity of laboratory animals, specifically an acce l e ration of reaction time to environmental s timuli. Small doses were admi nister e d to pigs, mice, guinea pigs, rats a nd rabbits and wer e observed to induce extr e mely r apid but highly coordinated movements such as lickin g , c h ewing , eating, drinking and scratch ing . These observa tions c losely resembled those seen by the administration of amph e t amine ( 1) . Pipradrol HCL i s alpha-(pipe ridyl)ben zh ydr o l hydr o­ c hloride. The hydrochl o ride salt is a white o do rless powder with a slightly bitter taste. One part dissolves in about 60 parts of hot wate r. Pipradrol is a lso k nown by trade n a mes s u c h as Alertol, Gadexyl, Ceptidrol, Meratonic a nd -1- 2 Metra tran ( 2). OH ~ 0 -?-0 I~ Pipradrol Amphetamine Considering the similarity between the action of pip- radrol and amphetamine on laboratory animals, it was ques- tioned as to whether or not the stereochemical e na ntiomers of pipradrol would also have differe nt pharmacological actions . Therefore, Portoghese and co-workers (3) con- ducted studi es on rat l ocomotor activity using enantiomers of pipradrol synthesized from (R)- a nd (S)- pipecolic acid. I t was found t h at all of the central stimulant activity was due to t h e (R)- pipradrol enantiomer while the more active enantiomer of amphetamine possessed the opposite con figura- tion . Because o f these steric differences in activity, it was suggested that these compounds may be acting on dif- ferent receptors in the central nervous system. The administration of lethal doses of pipradrol intra- venous ly to mice, rats , guinea pigs and rabbits caused 3 tremors and convulsions with death occurring during the con- vulsive stage due to respiratory failure. Lethal doses given orally to dogs caused an increase in motor activity (circling and rolling) with the animals becoming less co- ordinated but rarely experiencing convulsions . Death occur- red suddenly during the hyperactivity stage. Early observations in dogs given pipradrol showed it to differ behaviorally from amphetamine in that the animals did not become irritable and remained amenable to handling whereas animals treated with amphetamines were easily ag- gravated (1). With these observations, pipradrol became classified pharmacologically as a psychomotor stimulant. Psychomotor stimulants are known to increase locomotor activity and to induce stereotyped behavior (4). Loco- motor activity in rats can be measured by means of a photo- cell cage utilizing two parallel photocell beams directed across the long axis of the cage. The number of inter- ruptions of the photocell beam indicates the degree of activity of the test animals. Stereotypic behavior in rats is usually manifested by continuous sniffing, licking or biting , grinding of the jaws, grooming, rearing and occasionally by backward locomotion (5) . Sahakian et al. (6) postulated that these two behaviors might be mediated by different mechanisms. Psychomotor stimulation can also facilitate operant performance such as that reinforced by electrical stimulation 4 - of the brain (7-9). Therefore, it has been suggested that = the increase in behavioral activity produced by psycho­ motor stimulants results from an increase in the value of the rewarding stimuli. This effect may be mediated by the potentiation of a brain reinforcement mechanism (10) .
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • 82 Acts, Ch 1044, §1, 2
    93 LA WS OF THE SIXTY-NINTH G.A., 1982 SESSION CH. 1044 CHAPTER 1044 SCHEDULE OF CONTROLLED SUBSTANCES S.F.2101 AN ACT amending the schedule of controlled substances. Be It Enacted by the General Assembly of the State of Iowa: Section 1. Section 204.204, subsection 2, Code 1981, is amended by adding the following new lettered paragraphs in alphabetical sequence and relettering the remaining paragraphs: NEW LETTERED PARAGRAPH. Alpha-Methylfentanyl (N-( l-(alpha-methyl-beta-phenyl) ethyl-4-piperidyI) propionanilide; 1-(1-methyl-2-phenylethyI)-4-(N -propanilido)piperidine). NEW LETTERED PARAGRAPH. Sufentanil. NEW LETTERED PARAGRAPH. Tilidine. Sec. 2. Section 204.204, Code 1981, is amended by adding after subsection 5 the following new subsection and renumbering the remaining subsections: NEW SUBSECTION. 6. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: a. Fenethylline. Sec. 3. Section 204.206, subsection 3, Code 1981, is amended by adding after paragraph c the following new lettered paragraph: NEW LETTERED PARAGRAPH. d. Bulk dextropropoxyphene (nondosage forms). Sec. 4. Section 204.206, Code 1981, is amended by adding the following new subsection: NEW SUBSECTION. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances: a. Immediate precursor to amphetamine and methamphetamine: (1) Phenylacetone. Sec. 5. Section 204.208, subsection 6, paragraph c, Code 1981, is amended by striking the paragraph.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Antagonism of Histamine-Activated Adenylate Cyclase in Brain by D
    Proc. Natl. Acad. Sci. USA Vol.74, No. 12, pp. 5697-5701, December 1977 Medical Sciences Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide (histaminergic antagonists/adenosine 3':5'-cyclic monophosphate/H2-receptors/ergots/D-2-bromolysergic acid diethylamide) JACK PETER GREEN, CARL LYNN JOHNSON, HAREL WEINSTEIN, AND SAUL MAAYANI Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, 100th Street and Fifth Avenue, New York, New- York 10029 Communicated by Vincent P. Dole, August 19, 1977 ABSTRACT D-Lysergic acid diethylamide and D-2-bro- (ED50; amount necessary to produce half-maximal response) molysergic acid diethylamide are competitive antagonists of and antagonist affinities (pA2) were not altered. the histamine activation of adenylate cyclase [ATP pyrophos- Adenylate Cyclase Assay. The assay system has been de- phate-lyase (cyclizing); E.C. 4.6.1.11 in broken cell preparations in All additions of the hippocampus and cortex of guinea pig brain. The ade- scribed (8). All assays were performed triplicate. nylate cyclase is linked to the histamine H2-receptor. Both D- were made to the assay tubes on ice. They were then transferred lysergic acid diethylamide and D-2-bromolysergic acid dieth- to a 30° shaking incubator and preincubated for 5 min to allow ylamide show topological congruency with potent H2-antago- the enzymatic activity to reach a steady state and to eliminate nists. D-2-Bromolysergic acid diethylamide is 10 times more the influence of any lag periods in hormone activation. After potent as an H2-antagonist than cimetidine, which has been the the preincubation period, 25 of [a-32PJATP (1-2 gCi) were most potent H2-antagonist reported, and D-lysergic acid di- pl ethylamide is about equipotent to cimetidine.
    [Show full text]
  • ARTICLE 33: NEW YORK STATE CONTROLLED SUBSTANCES ACT As of January 26, 2017 +
    ARTICLE 33: NEW YORK STATE CONTROLLED SUBSTANCES ACT As of January 26, 2017 + Notice The information contained in this document is not the official version of the New York State Public Health Law. No representation is made as to its accuracy. To ensure accuracy and for evidentiary purposes, reference should be made to the official version available on the New York State Legislature Web site. Click on the link for "Laws of New York" and then the link for "PBH Public Health". Page TITLE 1 – GENERAL PROVISIONS 3300 - Short Title 4 3300a- Legislative purposes 4 3301 - Applicability of this article to actions and matters occurring or arising before and after the effective date. 4 3302 - Definitions of terms of general use in this article 4 3304 - Prohibited acts 7 3304* - Prohibited acts 8 3305 - Exemptions 8 3306 - Schedules of controlled substances 9 3307 - Exception from schedules 23 3308 - Powers and duties of the commissioner 24 3309 - Opioid overdose prevention 24 3309a - Prescription pain medication awareness program 26 TITLE 2 – MANUFACTURE AND DISTRIBUTION OF CONTROLLED SUBSTANCES 3310 - Licenses for manufacture or distribution of controlled substances 28 3311 - Authority to issue initial licenses, amended licenses and to renew licenses 29 3312 - Application for initial license 29 3313 - Granting of initial license 29 3315 - Applications for renewal of licenses to manufacture or distribute controlled substances 30 3316 - Granting of renewal of licenses 30 3318 - Identification of controlled substances 31 3319 - Distribution of free
    [Show full text]
  • 5994392 Tion of Application No. 67375.734 Eb3-1685, PEN. T
    USOO5994392A United States Patent (19) 11 Patent Number: 5,994,392 Shashoua (45) Date of Patent: Nov.30, 1999 54 ANTIPSYCHOTIC PRODRUGS COMPRISING 5,120,760 6/1992 Horrobin ................................. 514/458 AN ANTIPSYCHOTICAGENT COUPLED TO 5,141,958 8/1992 Crozier-Willi et al. ................ 514/558 AN UNSATURATED FATTY ACID 5,216,023 6/1993 Literati et al. .......................... 514/538 5,246,726 9/1993 Horrobin et al. ....................... 424/646 5,516,800 5/1996 Horrobin et al. ....................... 514/560 75 Inventor: Victor E. Shashoua, Brookline, Mass. 5,580,556 12/1996 Horrobin ................................ 424/85.4 73 Assignee: Neuromedica, Inc., Conshohocken, Pa. FOREIGN PATENT DOCUMENTS 30009 6/1981 European Pat. Off.. 21 Appl. No.: 08/462,820 009 1694 10/1983 European Pat. Off.. 22 Filed: Jun. 5, 1995 09 1694 10/1983 European Pat. Off.. 91694 10/1983 European Pat. Off.. Related U.S. Application Data 59-025327 2/1984 Japan. 1153629 6/1989 Japan. 63 Continuation of application No. 08/080,675, Jun. 21, 1993, 1203331 8/1989 Japan. abandoned, which is a continuation of application No. 07/952,191, Sep. 28, 1992, abandoned, which is a continu- (List continued on next page.) ation of application No. 07/577,329, Sep. 4, 1990, aban doned, which is a continuation-in-part of application No. OTHER PUBLICATIONS 07/535,812,tion of application Jun. 11, No. 1990, 67,375.734 abandoned, Eb3-1685, which is a continu-PEN. T. Higuchi et al. 66 Prodrugs as Noye Drug Delivery Sys 4,933,324, which is a continuation-in-part of application No.
    [Show full text]
  • Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE
    Novel Psychoactive Treatment UK Network NEPTUNE Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE This publication of the Novel Psychoactive Treatment UK Network (NEPTUNE) is protected by copyright. The reproduction of NEPTUNE guidance is authorised, provided the source is acknowledged. © 2015 NEPTUNE (Novel Psychoactive Treatment UK Network) 2015 Club Drug Clinic/CAPS Central and North West London NHS Foundation Trust (CNWL) 69 Warwick Road Earls Court SW5 9HB http://www.Neptune-clinical-guidance.com http://www.Neptune-clinical-guidance.co.uk The guidance is based on a combination of literature review and expert clinical con sensus and is based on information available up to March 2015. We accept no responsi bility or liability for any consequences arising from the use of the information contained in this document. The recommended citation of this document is: Abdulrahim D & Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Novel Psychoactive Treatment UK Network (NEPTUNE). London, 2015. NEPTUNE is funded by the Health Foundation, an independent charity working to improve the quality of health care in the UK. Editorial production and page design by Ralph Footring Ltd, http://www.footring.co.uk NEPTUNE Chapter 11 Pipradrols and pipradrol derivatives Pipradrols and pipradrol derivatives are a group of amphetamine-type substances (ATS) structurally related to methamphetamines. In recent years, 2-DPMP (desoxy- pipradrol, also known as 2-diphenylmethylpiperadine) and D2PM (diphenylprolinol) have appeared on the recreational drug market, initially as so-called legal highs.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,773,457 Nahoum (45) Date of Patent: Jun
    USOO5773457A United States Patent (19) 11 Patent Number: 5,773,457 Nahoum (45) Date of Patent: Jun. 30, 1998 54) COMPOSITIONS 4,863,911 9/1989 Anderson et al.. 4,931,445 6/1990 Goldstein et al.. 75 Inventor: Cesar Roberto Dias Nahoum, 5,059.603 10/1991 Rubin. SmithKline Beechman Corporation 5,145,852 9/1992 Virag. Corporate Intellectual Property, 5,147,855 9/1992 Gozes et al.. 5,177,070 1/1993 Katz. UW2220 P.O. Box 1539, King of 5.190,9672----- Y-2 3/1993 Riley. Prussia, Pa. 19406-0939 5,192,806 3/1993 Pill et al.. 5,214,030 5/1993 Stief. 73 Assignee: Cesar Roberto Dias Nahoum, Rio de 5.242,391 9/1993 Place et al.. Janeiro, Brazil 5,256,652 10/1993 El-Rashidy. 5,270,323 12/1993 Milne et al.. 21 Appl. No.: 444,130 5,336,678 8/1994 Cavallini. 9 5,474,535 12/1995 Place et al.. 22 Filled: Mayy 18,18, 1995 5,565,466 10/1996 Gioco et al. ............................ 514/400 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 0 266968 A2 5/1988 European Pat. Off.. 63 Continuation of Ser. No. 381,945, Feb. 15, 1995. O 432 199 B1 9/1989 European Pat. Off.. 6 O 346 297 A1 12/1989 European Pat. Off.. 51) Int. Cl. ................................................... A61K 31/415 0.357 581 A1 3/1990 European Pat. Off.. 52 U.S. Cl. ............................................. 514/397; 514/400 0.357581. B1 3/1990 European Pat. Off.. 58 Field of Search ..................................... 514/400, 397, O 459377 A2 12/1991 European Pat.
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Dimaprit (hydrochloride) Item No. 29418 CAS Registry No.: 23256-33-9 Formal Name: carbamimidothioic acid, 3-(dimethylamino)propyl ester, dihydrochloride NH MF: C H N S • 2HCl 6 15 3 H N S N FW: 234.2 2 Purity: ≥95% • 2HCl Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Dimaprit (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the dimaprit (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Dimaprit (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of dimaprit (hydrochloride) in these solvents is approximately 30 mg/ml. Dimaprit (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, dimaprit (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Dimaprit (hydrochloride) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description 1,2 Dimaprit is a histamine H2 receptor agonist with a Ki value of 44 µM in guinea pig right atrium. It is selective for histamine H2 over H1 and H3 receptors with relative potencies of 71, <0.0001, and <0.008, respectively, compared to histamine. Dimaprit (6 μM) inhibits histamine release from isolated peritoneal mast cells in a rat model of anaphylaxis induced by A.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]